enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study
Key Highlights
- ➤TAVVE pivotal study’s first 10-patient stage expected to begin before year end
- ➤Part 2 plans 220 randomized patients, including 165 receiving the enVVe System
- ➤Cash and investments totaled $18.5 million, funding operations into fourth quarter 2027
- ➤Quarterly operating expenses fell to $4.5 million from $4.9 million year over year
- ➤2027 first-half cash burn expected to increase to $4 million-$5 million
Expert Statements
Robert Berman, Chief Executive Officer of enVVeno Medical
“Clinical sites for Part 1 of TAVVE pivotal study are being activated and coming online and we are on schedule to enroll our first patient before the end of the year.”
Robert Berman, Chief Executive Officer of enVVeno Medical
“We did a nice job of managing our operating expenses in the quarter while still pursuing our immediate priority of getting the TAVVE pivotal study underway.”
IRVINE, CA / ACCESS Newswire / October 30, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the third quarter ended September 30, 2026. Cash and investments at the end of the quarter were $18.5 million, with a quarterly burn of approximately $3 million. The Company is on track to begin Part 1 of the TAVVE(®) U.S. pivotal study for its enVVe(®) system, a first-in-class, non-surgical replacement venous valve, in the fourth quarter of this year. The study is being conducted under an FDA-approved Investigational Device Exemption (IDE).
"Clinical sites for Part 1 of TAVVE pivotal study are being activated and coming online and we are on schedule to enroll our first patient before the end of the year," said Robert Berman, Chief Executive Officer of enVVeno Medical. "We did a nice job of managing our operating expenses in the quarter while still pursuing our immediate priority of getting the TAVVE pivotal study underway."
Get started
Create a free account to read the full story.